LDR meets $75m IPO target
This article was originally published in Clinica
Executive Summary
Spinal implant specialist LDR has launched its initial public offering (IPO), reportedly raising the $75m it had hoped for, selling five million shares at $15 apiece. The firm had previously upped its target from the $69m it had originally been aiming for (www.clinica.co.uk, 20 September 2013). The Austin, Texas company estimates that the net proceeds from the offering will be around $66.8m, or $77.2m if the underwriters exercise their overallotment option in full, it said in a filing with the US Securities and Exchange Commission (SEC). LDR will list on the Nasdaq Global Select market under the ticker symbol LDRH. The firm’s flagship products are based on its VerteBRIDGE fusion and Mobi non-fusion platforms, which are both designed for use in the cervical and lumbar spine.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.